V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320005683 | 320004028 | 1.61 | 67.4 | Curative (C) | 2017-03-17 | 2017-04-18 | ICON8B TRIAL | N | N | 320023709 | NIRAPARIB |
| 320005684 | 320004030 | 1.76 | 90 | Palliative (P) | 2017-12-15 | 2017-12-17 | Irinotecan + Modified De Gramont | N | N | 320023709 | AFLIBERCEPT + FU + IRINOTECAN |
| 320005685 | 320004031 | null | 79.1 | Curative (C) | null | 2015-06-08 | CARBOPLATIN + RT | null | null | 320023757 | CISPLATIN + ETOPOSIDE |
| 320005686 | 320004033 | 1.6 | 54.4 | Curative (C) | 2018-04-25 | 2018-04-30 | Cisplatin + Vinorelbine (IV) | N | Y | 320023767 | CARBOPLATIN + DOCETAXEL |
| 320005687 | 320004034 | 1.87 | null | Palliative (P) | null | 2016-06-24 | FLUOROURACIL + MITOMYCIN | null | null | 320023768 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 320005688 | 320005849 | 1.77 | 70 | Palliative (P) | 2015-12-27 | 2015-12-31 | IVADo | 02 | N | 320023794 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320005689 | 320005849 | 1.75 | 51.4 | Adjuvant (A) | 2013-04-17 | 2013-04-17 | Topotecan (intravenous) | N | N | 320023794 | PEMBROLIZUMAB |
| 320005690 | 320005849 | null | 61.5 | Palliative (P) | 2014-09-15 | 2014-11-27 | Carboplatin + Cetux + FU (>Cycle 2) | 02 | N | 320023794 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320005691 | 320004035 | 1.72 | 33.9 | Palliative (P) | null | 2014-07-28 | EOX | null | null | 320023808 | CETUXIMAB + CISPLATIN + FU |
| 320005692 | 320004036 | 1.43 | 71.7 | Palliative (P) | 2017-11-01 | 2017-11-09 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | 320023820 | LANREOTIDE |
| 320005693 | 320004037 | null | 113.9 | Palliative (P) | 2016-06-26 | 2016-06-27 | Bevacizumab+Carbo+Pacliaxel | Y | N | 320023826 | CARBOPLATIN + ETOPOSIDE |
| 320005694 | 320004038 | null | null | Curative (C) | 2016-01-31 | 2016-03-20 | CISPLATIN + DOCETAXEL + FLUOROURACIL | Y | N | 320023826 | CETUXIMAB + RT |
| 320005695 | 320004039 | 1.59 | 75.4 | Palliative (P) | 2018-03-07 | 2018-04-22 | Docetaxel 75mg/m2 (21 day) | N | N | 320023838 | CETUXIMAB + CISPLATIN + FU |
| 320005696 | 320004043 | 1.54 | 79.5 | Adjuvant (A) | 2018-04-23 | 2018-04-24 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | N | 320023860 | VAI |
| 320005697 | 320004045 | 1.71 | 87 | Palliative (P) | 2016-12-23 | 2017-01-08 | VAC | N | N | 320023872 | CAPECITABINE + MITOMYCIN + RT |
| 320005698 | 320004046 | 1.59 | 52.3 | Palliative (P) | 2016-08-22 | 2016-08-30 | Fluorouracil PVI + Mitomycin 42 day | 02 | N | 320023894 | OCTOPUS TRIAL |
| 320005699 | 320004047 | 1.79 | 56.5 | null | 2018-01-09 | 2018-01-23 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 02 | N | 320023897 | GEMCITABINE |
| 320005700 | 320004048 | 1.8 | 71 | Palliative (P) | 2018-01-18 | 2018-01-22 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320023905 | CETUXIMAB + RT |
| 320005701 | 320004048 | null | 58.8 | Adjuvant (A) | 2017-08-19 | 2017-08-25 | CAPECITABINE + IRINOTECAN | 2 | N | 320023905 | CETUXIMAB + CISPLATIN + FU |
| 320005702 | 320004050 | 1.59 | 54.8 | Palliative (P) | 2016-12-24 | 2016-12-25 | Atezolizumab | 02 | N | 320023912 | ATEZOLIZUMAB |
| 320005703 | 320004051 | 1.8 | 64.8 | Palliative (P) | null | 2015-09-01 | CETUXIMAB + OXALIPLATIN + MDG | N | N | 320023924 | POUT TRIAL |
| 320005704 | 320004055 | 0 | 62 | Palliative (P) | null | 2017-06-15 | STS Rhabdo RMS 2005 Vin Cyclo | null | null | 320023924 | CETUXIMAB + CISPLATIN + FU |
| 320005705 | 320006714 | 1.76 | -1 | Palliative (P) | null | 2018-01-23 | PEMBROLIZUMAB | null | null | 320023940 | IPILIMUMAB |
| 320005706 | 320004056 | 1.71 | 62 | Palliative (P) | 2014-09-28 | 2015-01-01 | Doxorubicin 75mg/m2 | Y | N | 320023942 | CETUXIMAB + CISPLATIN + FU |
| 320005707 | 320004057 | 1.6 | 66.1 | Neo-adjuvant (N) | 2015-06-23 | 2015-07-16 | Cetuximab + CISPLATIN + FLUOROURACIL | null | null | 320023958 | CAPECITABINE + OXALIPLATIN |
| 320005708 | 320004059 | 1.61 | 61.8 | Adjuvant (A) | 2017-11-15 | 2017-11-18 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | 320023958 | PAC-PLAT |
| 320005709 | 320004061 | null | 116.4 | Curative (C) | 2014-07-23 | 2014-08-18 | TCF | N | N | 320023993 | NIVOLUMAB |
| 320005710 | 320004062 | 1.85 | 96.5 | Adjuvant (A) | 2017-05-13 | 2017-06-08 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 320023994 | CYCLOPHOSPHAMIDE + VINORELBINE |
| 320005711 | 320004062 | null | 29.1 | Palliative (P) | 2016-01-11 | 2016-02-12 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 320023994 | CISPLATIN + PACLITAXEL |
| 320005712 | 320004064 | 1.64 | 61.1 | Palliative (P) | 2016-06-11 | 2016-10-22 | Ifosfamide + Liposomal Doxorubicin | N | N | 320024003 | CETUXIMAB + RT |
| 320005713 | 320004065 | 1.58 | 78 | Neo-adjuvant (N) | 2015-08-10 | 2015-08-24 | POUT TRIAL | N | N | 320024014 | ICON8B TRIAL |
| 320005714 | 320004066 | 0 | 72 | Palliative (P) | 2013-12-04 | 2013-12-07 | NIVOLUMAB | 01 | N | 320024026 | MITOMYCIN INTRAVESICULAR |
| 320005715 | 320004068 | null | 70.5 | Palliative (P) | 2013-10-06 | 2013-11-04 | Docetaxel 75mg/m2 (21 day) | 02 | N | 320024027 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320005716 | 320004071 | 1.6 | 59.2 | Palliative (P) | 2014-08-05 | 2014-08-05 | Doxorubicin + Gemcitabine | 02 | N | 320024027 | CETUXIMAB + CISPLATIN + FU |
| 320005719 | 320004074 | 1.72 | 79.6 | Palliative (P) | 2017-03-11 | 2017-03-11 | Vemurafenib | N | N | 320024034 | VEMURAFENIB |
| 320005720 | 320004075 | 1.62 | 50.3 | Disease modification (D) | 2017-09-05 | 2017-09-20 | Cyclophosphamide + Docetaxel | N | N | 320024052 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320005721 | 320004077 | 1.7 | 71.3 | Palliative (P) | 2017-06-29 | 2017-07-13 | TCF | N | N | 320024058 | PEMBROLIZUMAB |
| 320005722 | 320005867 | 1.57 | 59.5 | Curative (C) | 2018-12-24 | 2019-02-04 | Atezolizumab | N | N | 320024060 | ICON8B TRIAL |
| 320005723 | 320004078 | 1.81 | 124 | Palliative (P) | 2016-04-26 | 2016-11-10 | Trabectedin | 02 | N | 320024060 | CAPECITABINE + CETUXIMAB + CISPLATIN |
| 320005724 | 320004078 | null | 75 | Curative (C) | 2017-01-15 | 2017-01-17 | CETUXIMAB + RT | N | N | 320024060 | RMS 2005 TRIAL |
| 320005725 | 320005869 | 1.78 | 82.7 | Palliative (P) | null | 2016-01-05 | PEMBROLIZUMAB | N | N | 320024075 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320005726 | 320004080 | 1.65 | 69 | Palliative (P) | 2014-06-23 | 2014-06-24 | PEMBROLIZUMAB | N | N | 320024083 | ECARBOF |
| 320005727 | 320004081 | 1.73 | 67.9 | Palliative (P) | 2016-09-13 | 2016-10-12 | Docetaxel 75mg/m2 (21 day) | N | N | 320024088 | DOXORUBICIN EMBOLISATION |
| 320005728 | 320004084 | 1.68 | 59 | Palliative (P) | 2017-03-25 | 2017-03-25 | ICON8 TRIAL | N | N | 320024091 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320005729 | 320004085 | 1.8 | null | Curative (C) | 2016-12-01 | 2016-12-02 | Everolimus 10mg | N | N | 320024091 | IRINOTECAN + MDG |
| 320005730 | 320004090 | 1.6 | 106.4 | Palliative (P) | 2014-12-25 | 2015-01-27 | EW EuroEwing 99 : VActC | null | null | 320000073 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320005731 | 320004091 | 1.71 | 72 | Not known (9) | 2016-09-29 | 2016-10-14 | EMA | N | N | 320000735 | CARBOPLATIN + VINCRISTINE |
| 320005732 | 320004091 | 1.59 | 52.5 | Palliative (P) | 2016-01-04 | 2016-01-11 | TEMOZOLOMIDE | N | N | 320000735 | BCG |
| 320005733 | 320004093 | 0 | null | Palliative (P) | null | 2017-11-12 | Temozolomide 200mg/m2 | Y | null | 320001321 | DOCETAXEL |
| 320005734 | 320004093 | 1.68 | 84.8 | Palliative (P) | 2017-05-27 | 2017-06-04 | LOMUSTINE + PROCARBAZINE | N | N | 320001321 | GEMCITABINE |